Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 439

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

Open access
Drilon, Alexander, Nagasubramanian, Ramamoorthy, Blake, James F., Ku, Nora, Tuch, Brian B., Ebata, Kevin, Smith, Steve, Lauriault, Veronique, Kolakowski, Gabrielle R., Brandhuber, Barbara J., Larsen, Paul D., Bouhana, Karyn S., Winski, Shannon L., Hamor, Robyn, Wu, Wen-I, Parker, Andrew, Morales, Tony H., Sullivan, Francis X., DeWolf, Walter E., Wollenberg, Lance A., Gordon, Paul R., Douglas-Lindsay, Dorothea N., Scaltriti, Maurizio, Benayed, Ryma, Raj, Sandeep, Hanusch, Bethany, Schram, Alison M., Jonsson, Philip, Berger, Michael F., Hechtman, Jaclyn F., Taylor, Barry S., Andrews, Steve, Rothenberg, S. Michael, Hyman, David M.·2017·Cancer Discovery

Abstract

Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histology-agnostic efficacy in patients with TRK fusion–positive cancers. Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited by acquired resistance. LOXO-195 is a selective TRK TKI designed to overcome acquired resistance mediated by recurrent kinase domain (solvent front and xDFG) mutations identified in multiple patients who have developed resistance to TRK TKIs. Activity against these acquired mutations was confirmed in enzyme and cell-based assays and in vivo tumor models. As clinical proof of concept, the first 2 patients with TRK fusion–positive cancers who developed acquired resistance mutations on larotrectinib were treated with LOXO-195 on a first-in-human basis, utilizing rapid dose titration guided by pharmacokinetic assessments. This approach led to rapid tumor responses and extended the overall duration of disease control achieved with TRK inhibition in both patients. Significance: LOXO-195 abrogated resistance in TRK fusion–positive cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs. This establishes a role for sequential treatment by demonstrating continued TRK dependence and validates a paradigm for the accelerated development of next-generation inhibitors against validated oncogenic targets. Cancer Discov; 7(9); 963–72. ©2017 AACR. See related commentary by Parikh and Corcoran, p. 934. This article is highlighted in the In This Issue feature, p. 920

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-0507

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 439

Metadata

Authors
Drilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., Smith, S., Lauriault, V., Kolakowski, G. R., Brandhuber, B. J., Larsen, P. D., Bouhana, K. S., Winski, S. L., Hamor, R., Wu, W.-I., Parker, A., Morales, T. H., Sullivan, F. X., DeWolf, W. E., Wollenberg, L. A., Gordon, P. R., Douglas-Lindsay, D. N., Scaltriti, M., Benayed, R., Raj, S., Hanusch, B., Schram, A. M., Jonsson, P., Berger, M. F., Hechtman, J. F., Taylor, B. S., Andrews, S., Rothenberg, S. M., & Hyman, D. M.
Venue
Cancer Discovery
Published
2017-08-31
Volume
7
Issue
9
Pages
963-972
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2620626563
Cited by
439
References
5
FWCI
32.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-0507
The paper
Drilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., Smith, S., Lauriault, V., Kolakowski, G. R., Brandhuber, B. J., Larsen, P. D., Bouhana, K. S., Winski, S. L., Hamor, R., Wu, W.-I., Parker, A., Morales, T. H., Sullivan, F. X., DeWolf, W. E., . . . Hyman, D. M. (2017). A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-0507

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.